GP Education and Resources


Alcohol Treatment Guidelines

The Guidelines for the Treatment of Alcohol Problems have been periodically developed over the past 25 years. The present version of the Guidelines was commissioned by the Commonwealth of Australia to remain current and integrated with the updated National Health and Medical Research Council (NHMRC) consumption guidelines (2020). Guidelines are available to download here.

National GP Education Package for Drug and Alcohol Treatment
Opioid Treatment

Opioid Treatment Accreditation Course (OTAC)

The University of Sydney provides free courses to train health professionals on behalf of the NSW Ministry of Health. The courses assist in the development of knowledge, skills, and practices to support the safe prescribing of opioid pharmacotherapies for the treatment of opioid dependence.

Medical and nurse practitioners can complete the Opioid Treatment Accreditation Course (OTAC), which forms part of the process to apply to recieve accreditation as an opioid pharmacotherapy prescriber.

There are 4 courses that are available to complete. Two of these courses (the Fundamentals of Opioid Treatment and OTAC) are related to the accreditation process; the other two are standalone topics relevant to prescribing opioid treatment.

For anyone seeking to complete any of the 4 courses, visit to register for an account. For medical and nurse practitioners, there are 3 steps to complete apply for OTP accreditation in NSW:

Have an enquiry? You can send an email or visit the website


Treatment of opioid dependency with Depot Buprenorphine

Interim guidelines for depot buprenorphine were developed to provide a framework for clinical decision making for clinicians and consumers in a range of service settings involved in the delivery of treatment of long acting depot buprenorphine products.

Clinical guidelines for use of depot buprenorphine (Buvidal® and Sublocade®) in the treatment of opioid dependence

Guidelines should be read in conjunction with the NSW Health Guidelines: Treatment of Opioid Dependence

This webinar aims to explain the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment for opioid dependency. The webinar is presented by Assoc Professor Nicholas Lintzeris, Clinical Director of South Eastern Sydney Local Health District on 16 June 2020

Webinar – Introduction to depot buprenorphine in the treatment of opioid dependent patients

Long acting depot buprenorphine was listed on the Pharmaceutical Benefits Scheme (PBS) on the 1st September 2019 as an s100 drug, making it free to people with an opioid dependency. This webinar explains the clinical guidance, evidence base, pharmacology, and risks associated with depot buprenorphine, and how to implement it as an Opioid Agonist Treatment (OAT) for opioid dependency.
Watch here

Webinar – Prescribing depot buprenorphine in primary care

From 3 April 2020, Buvidal® – one of the two depot buprenorphine formulations available for the treatment of opioid dependency – will be able to be prescribed in the primary care setting.

This webinar will help GPs identify patients suitable for depot buprenorphine, implement depot buprenorphine as an OAT for opioid dependency, specifically in relation to prescribing, induction, dose alterations & reduction off the drug, incorporate treatment with depot buprenorphine into your practice and comply with regulatory requirements of prescribing and storing of depot buprenorphine.
Watch here

Webinar – Using Opioid Agonist Treatment for Pharmaceautical Opioid Dependence 

Watch here

Other Resources
20221031 Iar Signature Banner V2